{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T14:13:25Z","timestamp":1771942405905,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.1016\/s0006-3223(03)00524-9","type":"journal-article","created":{"date-parts":[[2003,10,11]],"date-time":"2003-10-11T05:52:40Z","timestamp":1065851560000},"page":"1241-1248","source":"Crossref","is-referenced-by-count":144,"title":["Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial"],"prefix":"10.1016","volume":"54","author":[{"given":"Jari","family":"Tiihonen","sequence":"first","affiliation":[]},{"given":"Tero","family":"Hallikainen","sequence":"additional","affiliation":[]},{"given":"Olli-Pekka","family":"Ryyn\u00e4nen","sequence":"additional","affiliation":[]},{"given":"Eila","family":"Repo-Tiihonen","sequence":"additional","affiliation":[]},{"given":"Irma","family":"Kotilainen","sequence":"additional","affiliation":[]},{"given":"Markku","family":"Eronen","sequence":"additional","affiliation":[]},{"given":"P\u00e4ivi","family":"Toivonen","sequence":"additional","affiliation":[]},{"given":"Kristian","family":"Wahlbeck","sequence":"additional","affiliation":[]},{"given":"Anu","family":"Putkonen","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0006-3223(03)00524-9_BIB1","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1994"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1001\/archpsyc.57.3.270","article-title":"Attenuation of the neuropsychiatric effects of ketamine with lamotrigine. Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists","volume":"57","author":"Anand","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB3","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1517\/14656566.3.10.1513","article-title":"Lamotrigine in the treatment of bipolar disorder","volume":"3","author":"Bowden","year":"2002","journal-title":"Expert Opin Pharmacother"},{"issue":"suppl 10","key":"10.1016\/S0006-3223(03)00524-9_BIB4","first-page":"18","article-title":"Long-term treatment of bipolar disorder with lamotrigine","volume":"63","author":"Calabrese","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/001316446002000104","article-title":"A coefficient of agreement for nominal scales","volume":"20","author":"Cohen","year":"1960","journal-title":"Educ Psychol Meas"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB6","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1977"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0006-8993(93)90989-Z","article-title":"Flunarizine inhibits both calcium-dependent and independent release of glutamate from synaptosomes and cultured neurones","volume":"606","author":"Cousin","year":"1993","journal-title":"Brain Res"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB8","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1111\/j.1471-4159.1989.tb07257.x","article-title":"Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia","volume":"52","author":"Deakin","year":"1989","journal-title":"J Neurochem"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/026988110101500409","article-title":"Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia","volume":"15","author":"Dursun","year":"2001","journal-title":"J Psychopharmacol"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB9","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/archpsyc.56.10.950","article-title":"Clozapine plus lamotrigine in treatment-resistant schizophrenia","volume":"56","author":"Dursun","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB11","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.157.5.826","article-title":"Placebo-controlled trial of glycine added to clozapine in schizophrenia","volume":"157","author":"Evins","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB12","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/00004714-200012000-00014","article-title":"The drug-placebo response curve","volume":"6","author":"Faraone","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB13","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0079-6123(08)60453-7","article-title":"The glutamate synapse in neuropsychiatric disorders","volume":"116","author":"Farber","year":"1998","journal-title":"Prog Brain Res"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB14","series-title":"Structured Clinical Interview for DSM-IV Axis I Disorders\u2014Patient Edition (SCID-I\/P, Version 2.0, 4\/97 revision)","author":"First","year":"1997"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB17","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0006-3223(98)00367-9","article-title":"A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia","volume":"45","author":"Goff","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB18","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1176\/appi.ajp.158.9.1367","article-title":"The emerging role of glutamate in the pathophysiology and treatment of schizophrenia","volume":"158","author":"Goff","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB15","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1176\/ajp.152.8.1213","article-title":"Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia","volume":"152","author":"Goff","year":"1995","journal-title":"Am J Psychiatry"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB16","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1176\/ajp.153.12.1628","article-title":"D-cycloserine added to clozapine for patients with schizophrenia","volume":"153","author":"Goff","year":"1996","journal-title":"Am J Psychiatry"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB19","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0006-8993(98)00180-2","article-title":"Lamotrigine may limit pathological excitation in the hippocampus by modulating a transient potassium outward current","volume":"791","author":"Grunze","year":"1998","journal-title":"Brain Res"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB20","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1192\/bjp.169.5.610","article-title":"Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia","volume":"169","author":"Heresco-Levy","year":"1996","journal-title":"Br J Psychiatry"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archpsyc.56.1.29","article-title":"Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia","volume":"56","author":"Heresco-Levy","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB22","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1345\/aph.1A102","article-title":"Lamotrigine update and its use in mood disorders","volume":"36","author":"Hurley","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB24","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1176\/ajp.151.8.1234","article-title":"Amelioration of negative symptoms in schizophrenia by glycine","volume":"151","author":"Javitt","year":"1994","journal-title":"Am J Psychiatry"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB26","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB25","first-page":"322","article-title":"The current status of neuroleptic therapy","volume":"50","author":"Kane","year":"1989","journal-title":"J Clin Psychiatry"},{"issue":"suppl 9","key":"10.1016\/S0006-3223(03)00524-9_BIB27","first-page":"35","article-title":"Treatment-resistant schizophrenic patients","volume":"57","author":"Kane","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB28","series-title":"Positive and Negative Syndrome Scale (PANSS) Rating Manual","author":"Kay","year":"1987"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB29","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1176\/appi.ajp.158.11.1930","article-title":"Elevated clozapine plasma level with lamotrigine","volume":"158","author":"Kossen","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"suppl 2","key":"10.1016\/S0006-3223(03)00524-9_BIB30","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1111\/j.1528-1157.1991.tb05882.x","article-title":"Neurochemical and behavioural aspects of lamotrigine","volume":"32","author":"Leach","year":"1991","journal-title":"Epilepsia"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB32","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis","volume":"58","author":"Marder","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB33","first-page":"664","article-title":"Activation of glutamatergic neurotransmission by ketamine","volume":"42","author":"Moghaddam","year":"1997","journal-title":"J Neurosci"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB34","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.281.5381.1349","article-title":"Reversal of phenocyclidine effects by a group II metabotropic glutamate receptor agonist in rats","volume":"281","author":"Moghaddam","year":"1998","journal-title":"Science"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB35","first-page":"467","article-title":"Attenuation of the neuropsychiatric effects of ketamine with lamotrigine","volume":"59","author":"Olney","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB36","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1961","journal-title":"Psychol Rep"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1176\/ajp.156.1.145","article-title":"Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia","volume":"156","author":"Potkin","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/ajp.154.4.457","article-title":"Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders","volume":"154","author":"Tollefson","year":"1997","journal-title":"Am J Psychiatry"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB40","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0006-3223(00)01026-X","article-title":"Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine","volume":"49","author":"Tollefson","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB39","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/archpsyc.55.3.250","article-title":"Depressive signs and symptoms in schizophrenia. A prospective blinded trial of olanzapine and haloperidol","volume":"55","author":"Tollefson","year":"1998","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB41","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0006-3223(98)00279-0","article-title":"D-serine added to antipsychotics for the treatment of schizophrenia","volume":"44","author":"Tsai","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB42","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1176\/ajp.156.11.1822","article-title":"D-serine added to clozapine for the treatment of schizophrenia","volume":"156","author":"Tsai","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/S0006-3223(03)00524-9_BIB43","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S0006-3223(96)00311-3","article-title":"Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients","volume":"40","author":"van Berckel","year":"1996","journal-title":"Biol Psychiatry"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322303005249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322303005249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T03:37:23Z","timestamp":1682566643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322303005249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["S0006322303005249"],"URL":"https:\/\/doi.org\/10.1016\/s0006-3223(03)00524-9","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2003,12]]}}}